ArticleBMC cancer2026
IL-23 as a potential mediator of immune evasion and therapeutic target in laryngeal squamous cell carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) is a prevalent and aggressive malignancy. Interleukin-23 (IL-23) and its receptor (IL-23R) have been identified as key modulators of the immune response in various cancers, but their role in LSCC remains unclear. This study aimed to examine the expression of IL-23, IL-23R, and FoxP3 + regulatory T cells (Tregs) in LSCC tissues and explore their potential involvement in immune modulation and tumor progression.
methodsImmunohistochemical staining was performed on 115 LSCC tissue samples to assess the expression of IL-23, IL-23R, and FoxP3 + Tregs. The relationship between IL-23 expression and immune cell infiltration, including CD8 + T cells and Tregs, was analyzed, and survival analysis was conducted. Public datasets (TCGA-HNSC, GSE103322) were utilized for bioinformatic validation.
resultsIL-23 was predominantly expressed in tumor cells and stromal immune cells within the TME, while IL-23R was primarily located on immune cells, especially in the invasive margin. IL-23 expression was positively correlated with Treg infiltration and negatively associated with CD8 + T cell density. However, no significant correlation was found between IL-23 expression and overall survival, potentially due to the study’s sample size limitations. Bioinformatic analysis of the TCGA-HNSC cohort confirmed elevated IL23A expression in tumors and revealed its positive correlation with immune infiltration scores, Treg signatures, and enrichment in immune-related pathways.
conclusionIL-23, through its interaction with IL-23R and Tregs, contributes to immune evasion in LSCC. Targeting the IL-23/IL-23R signaling axis may offer a novel therapeutic approach to enhance anti-tumor immunity in LSCC. Larger cohort studies are needed to validate these findings and assess IL-23’s clinical utility as a biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.